ARS Pharmaceuticals’ needle-free neffy targets an underpenetrated $3.5–$4.0 billion market, but formulary access, cash burn, and execution must improve to unlock its substantial long-term upside.
Overview
ARS Pharmaceuticals is a commercial-stage biopharmaceutical company whose value is concentrated in neffy, the first FDA-approved needle-free epinephrine nasal spray for anaphylaxis. The product targets a persistent barrier to emergency treatment: fear and hesitation around traditional injectors, in a U.S. market where approximately 20 million people have severe Type I allergies but only about 3.5 million active epinephrine prescriptions are filled annually. Neffy’s U.S. label has expanded to pediatric patients weighing 15 kg and above, with no lower age limit, while ALK-Abelló supports international commercialization. Q2 2026 revenue increased 114% year over year to **$33.66 million**, beating consensus, but a **$62.3 million GAAP net loss**, $95.1 million of operating expenses, and 62% neffy gross margin highlighted launch costs and early manufacturing inefficiencies. Following a missed EPS estimate, delayed PBM access, and leadership changes, the share price fell to $4.20; the company’s market capitalization was $417.1 million and EV $369.9 million, or 3.6x TTM sales. Management is cutting H2 cash SG&A and R&D by more than 40% and targets cash-flow breakeven by late 2027. Key near-term catalysts are the January 2027 CVS Caremark decision, ARS-2 Phase 2b data in Q1 2027, and evidence that cost reductions are taking hold.